Single-center Study of Gustation in Idiopathic Parkinson's Disease and Lewy Body Disease Using Gustatory Evoked Potential Analysis
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DIJON · May 28, 2024
Trial Information
Current as of February 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how taste works in people with early-stage Parkinson's disease and Lewy body disease, compared to healthy individuals. The researchers want to understand whether there are differences in how these groups process taste, which could help us learn more about the effects of these conditions on the brain. Participants will include healthy volunteers, as well as patients who have been diagnosed with either early Parkinson's or Lewy body disease.
To join the study, you need to be an adult, have a Body Mass Index (BMI) under 30, and be able to give your consent (agreement to participate). Participants will need to fast for at least two hours before a taste test is conducted. Throughout the study, you may share information about your nutrition, movement, and thinking abilities, as these will also be compared among the groups. This study could provide valuable insights into how these diseases affect taste perception and brain function.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Healthy volunteers:
- • Person who has given written consent
- • Adult
- • Enrolled in the national register of healthy volunteers
- • Fasting \> 2 hours before PEG measurement
- • Body Mass Index (BMI) \< 30 kg/m².
- • No cognitive complaints and normal neurological assessment
- Patients with idiopathic Parkinson's disease:
- • Person who has given written consent
- • Adult
- • Fasting \> 2 hours before PEG measurement
- • Body Mass Index (BMI) \< 30 kg/m².
- • Diagnostic criteria for established or probable IPD
- Patients with Lewy body disease:
- • Person who has given written consent
- • Adult
- • Fasting \> 2 hours prior to PEG measurement
- • Body Mass Index (BMI) \< 30 kg/m².
- • Diagnostic criteria for probable or possible LBD
- Exclusion Criteria:
- • Non-affiliated to national health insurance
- • Person under legal protection (curatorship, guardianship)
- • Person subject to a court order
- • Pregnant, parturient or breast-feeding women
- • Major unable to give consent
- • MMSE score \< 15 and/or MoCA \< 10
- • Known infection with COVID-19 in the 6 months prior to inclusion
- • Active smoker (\> 4 cigarettes per day on a regular basis)
- • Subject with pacemaker (contraindication for bioelectrical impedancemetry)
- • Diabetic (type 1 or type 2)
- • Taking medication (in progress at the time of the study) that interferes with gustation
About Centre Hospitalier Universitaire Dijon
The Centre Hospitalier Universitaire Dijon (CHU Dijon) is a leading academic medical institution in France, dedicated to advancing healthcare through innovative research and clinical trials. With a focus on patient-centered care, CHU Dijon integrates comprehensive medical services with cutting-edge research initiatives across various specialties. The institution is committed to enhancing clinical outcomes and improving health standards by facilitating rigorous scientific investigations and collaborations with national and international partners. By prioritizing ethical practices and adherence to regulatory standards, CHU Dijon aims to contribute significantly to the development of new therapies and medical technologies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dijon, , France
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0